| (USD) | Mar 2024 | Q/Q |
|---|---|---|
| Revenue | 11.9B | +3% |
| Gross Profit | 8.9B | - |
| Cost Of Revenue | 2.9B | +7% |
| Operating Income | -11.5B | -788% |
| Operating Expenses | 20.4B | - |
| Net Income | -11.9B | -776% |
| R&D | 2.7B | +9% |
| G&A | 2.4B | +14% |
| Amortization | 2.4B | +4% |
| Interest Expense | 425MM | +34% |
| Restructuring & Acquisition | 312MM | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Bristol Myers Squibb (BMY) shares are trading lower Thursday afternoon following the pharmaceutical company's announcement of several cost-cutting initiatives. Among the measures were workforce reductions and the termination of approximately 12 drug development programs. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Angel Smith.
AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted first-quarter revenues of $11.9 billion, beating the consensus of $11.5 billion, an increase of 5% year-over-year, or 6% when adjusted for foreign exchange impacts, primarily driven by Eliquis, Reblozyl, and Opdualag, partially offset by Opdivo and Revlimid. Growth Portfolio worldwide revenues increased to $4.8 billion, up 8% or 11% when adjusted for foreign exchange impacts. This increase was primarily driven by higher demand for Reblozyl, O
Update: Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance -- Shares Fall
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Investors didn't like the biopharmaceutical company's updated guidance.
Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.
Bristol-Myers Squibb’s market capitalization has dropped so much over the past year that it is now arguably no longer part of the big pharma club. After reporting disappointing earnings figures on Thursday, the company’s shares fell sharply, giving it a market capitalization of about $95 billion. The problem for Bristol-Myers is that its older blockbuster products, cancer drug Revlimid and blood thinner Eliquis, are expected to decline in the coming years and investors aren’t convinced that th...
Bristol-Myers Squibb will shed 2,200 employees this year as part of a cost-cutting effort to save $1.5 billion by the end of 2025. Chief Finance Officer David Elkins said that the job cuts are part of an effort to become more agile, and aim at "removing layers of management so decisions get made more quickly.” Company executives said the plan is to reinvest in the most promising drug-development programs that are most likely to produce high returns.